Eranga R Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S Silveira, Nabeel Bardeesy
PURPOSE: FGFR2 and FGFR3 show oncogenic activation in many cancer types, often through chromosomal fusion or extracellular domain mutation. FGFR2 and FGFR3 alterations are most prevalent in intrahepatic cholangiocarcinoma (ICC) and bladder cancers, respectively, and multiple selective reversible and covalent pan-FGFR tyrosine kinase inhibitors (TKIs) have been approved in these contexts. However, resistance, often due to acquired secondary mutations in the FGFR2/3 kinase domain, limits efficacy...
March 4, 2024: Clinical Cancer Research